Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol
Journal of Ocular Pharmacology and Therapeutics · 2025
DOI: 10.1089/jop.2024.0112 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2025. Verfasst von Jeremy C Reitinger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana. Hauptthemen laut MEDLINE: Latanoprost, Timolol, Intraocular Pressure, Antihypertensive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
Purpose
To identify reasons for variable intraocular pressure (IOP) responses to latanoprost and timolol in healthy volunteers and to generate the control group as part of Eye Dynamics and Engineering Network.
Methods
In this multicenter, randomized, crossover study (NCT01677507), both eyes of 106 healthy subjects (212 eyes) were treated with latanoprost or timolol for 7 days, with a 6-week washout between treatments. Ocular biometrics, tonometry, and aqueous humor dynamics (AHD) were assessed at baseline and day 8 of each treatment. Subjects were divided into responders and nonresponders using cutoffs of >15% or >10% IOP reduction. Treatment effects and correlations were analyzed with paired t-tests.
Results
More subjects responded to latanoprost (54%) than timolol (27%) at >15% cutoff (p < 0.01). Responders had higher mean baseline IOP than nonresponders for both drugs at both cutoffs (p < 0.01). Among timolol nonresponders (n = 56), 39% responded to latanoprost in both eyes, 20% in one eye, and 41% in neither. Among latanoprost nonresponders (n = 31), 13% responded to timolol in both eyes, 13% in one eye, and 74% in neither. Latanoprost increased uveoscleral outflow, while timolol reduced aqueous flow and outflow facility. Low baseline uveoscleral outflow was associated with latanoprost response.
Conclusions
Higher baseline IOP predicted better responses to both drugs. Higher baseline uveoscleral outflow predicted nonresponse to latanoprost. No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana.
- Department of Ophthalmology and Visual Sciences, The Ohio State University, Columbus, Ohio.
- Department of Ophthalmology and Visual Sciences, Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska.
- Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.
- Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan.
ORCID-Profile: David M Reed, Cameron Peres, Sayoko E Moroi, Carol B Toris
Förderung
- NEI NIH HHS
Zitieren
APA
Reitinger, J. C., Reed, D. M., Peres, C., Fan, S., Gulati, V., Kazemi, A., Sit, A. J., Moroi, S. E., & Toris, C. B. (2025). Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2024.0112
Vancouver
Reitinger JC, Reed DM, Peres C, Fan S, Gulati V, Kazemi A, et al. Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol. Journal of Ocular Pharmacology and Therapeutics. 2025. doi:10.1089/jop.2024.0112
BibTeX
@article{Reitinger2025,
author = {Reitinger, Jeremy C and Reed, David M and Peres, Cameron and Fan, Shan and Gulati, Vikas and Kazemi, Arash and Sit, Arthur J and Moroi, Sayoko E and Toris, Carol B},
title = {Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2025},
doi = {10.1089/jop.2024.0112}
}
EUVIMED